Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Eli Lilly Insulin Drug Price Tripled While Trump's HHS Nominee Was President of the U.S. Unit

  • Post author:Sam
  • Post published:November 16, 2017
  • Post category:BioPharma

Azar, the new HHS nominee, is being pitched as someone who will help lower the price of prescription drugs. Source: BioSpace

Continue ReadingEli Lilly Insulin Drug Price Tripled While Trump's HHS Nominee Was President of the U.S. Unit

Arbutus' LNP Licensee Alnylam Initiates Rolling Submission of NDA to U.S. FDA for Patisiran

  • Post author:Sam
  • Post published:November 16, 2017
  • Post category:BioPharma

This submission allows the FDA to review completed portions of the NDA on an ongoing basis. Alnylam expects to submit final clinical data by year end. Source: BioSpace

Continue ReadingArbutus' LNP Licensee Alnylam Initiates Rolling Submission of NDA to U.S. FDA for Patisiran

scPharmaceuticals Nabs $89.6M in IPO

  • Post author:Sam
  • Post published:November 16, 2017
  • Post category:BioPharma

The company's common stock will begin trading on the Nasdaq under the ticker symbol "SCPH" today. Source: BioSpace

Continue ReadingscPharmaceuticals Nabs $89.6M in IPO

FDA Extends Review for Lipocine's TLANDO; Advisory Committee Meeting Date of January 10, 2018 Rem…

  • Post author:Sam
  • Post published:November 16, 2017
  • Post category:BioPharma

The FDA has assigned a new Prescription Drug User Fee Act goal date of May 8, 2018. Source: BioSpace

Continue ReadingFDA Extends Review for Lipocine's TLANDO; Advisory Committee Meeting Date of January 10, 2018 Rem…

All Systems Go: Johnson & Johnson Reaches Out for Second Ionis GI Drug

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

Ionis Pharma and Janssen have strengthened their alliance with a second deal for gastrointestinal drugs. Source: BioSpace

Continue ReadingAll Systems Go: Johnson & Johnson Reaches Out for Second Ionis GI Drug

Don't Stop Believing: Teva's R&D Head Gives 3 Reasons Why Investors Should Hold On

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

Teva's stock jumped as investors get more hopeful about the future. Source: BioSpace

Continue ReadingDon't Stop Believing: Teva's R&D Head Gives 3 Reasons Why Investors Should Hold On

Merit Medical Coughs Up $100M for Bard, BD's Biopsy Assets

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

Shares of Merit Medical Systems have jumped more than 9 percent this morning after the company announced it plunked down $100M for two product lines belonging to Becton, Dickinson and…

Continue ReadingMerit Medical Coughs Up $100M for Bard, BD's Biopsy Assets

FDA Berates Lupin for Repeatedly Making Pills That Don't Meet Quality Standards

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

In 2015 and 2016, the FDA found 134 instances when drugs or active ingredients failed initial testing but the company chose to override the results. Source: BioSpace

Continue ReadingFDA Berates Lupin for Repeatedly Making Pills That Don't Meet Quality Standards

With Merck Footing the $200M Bill, Moderna Launches mRNA Cancer Vaccine Clinical Trial

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

Moderna announced that it has dosed its first patient in a Phase I trial of mRNA-4157, a mRNA-based personalized cancer vaccine. Source: BioSpace

Continue ReadingWith Merck Footing the $200M Bill, Moderna Launches mRNA Cancer Vaccine Clinical Trial

Johns Hopkins Gets a $65M Boost to Take Promising Drugs Into Clinic

  • Post author:Sam
  • Post published:November 15, 2017
  • Post category:BioPharma

Deerfield and Johns Hopkins announce Bluefield Innovations, a collaboration designed to catalyze the development of early stage therapeutics. Source: BioSpace

Continue ReadingJohns Hopkins Gets a $65M Boost to Take Promising Drugs Into Clinic
  • Go to the previous page
  • 1
  • …
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • …
  • 288
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.